Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia

NCT05314582

Hematuria Retention, Urinary Operative Bleeding +1 more

COMPLETED

Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients

NCT02288780

BPH

TERMINATED

The Risk Factor and Outcome of Transient Incontinence After Prostate Enucleation Surgery

NCT05116592

Benign Prostatic Hyperplasia Incontinence

UNKNOWN

Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia

NCT02822924

Benign Prostate Hyperplasia

COMPLETED NA

Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate

NCT01073241

Benign Prostatic Hyperplasia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Non anticoagulant and/or antiplatelet users.

No interventions assigned to this group

B

Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.

No interventions assigned to this group

C

Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted to National Cheng Kung University Hospital Urology during the study
* Older than 20 years old
* Agree to participate this study
* Receiving transurethral resection of the prostate for benign prostatic hyperplasia or prostate cancer